Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 3/2015

01.09.2015 | Health Economics (N Khera, Section Editor)

Financial Hardship—an Unwanted Consequence of Cancer Treatment

verfasst von: Julie McNulty, Nandita Khera

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The substantial economic burden of cancer is increasingly being shifted to patients. Financial burden experienced by patients as a result of medical treatment has an impact on their lifestyle choices, health behaviors, and quality of life. Variation in treatment recommendations based on the patients’ economic status or affordability may be against the basic tenet of social justice and is a growing challenge for policy makers. This review summarizes the multifaceted constructs and current trends associated with financial hardship within the context of cancer care and healthcare economics focusing mainly on hematological malignancies but supplemented by nonhematological cancer and general medical literature. We also highlight the patient and physician perspectives about this issue and identify important areas for future research. We discuss the need for more proactive solutions so that patients can achieve good clinical outcomes, without catastrophic financial consequences for themselves and their families.
Literatur
1.
Zafar SY, Abernethy A. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park). 2013;27(2):80–1.
2.•
Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381–90. The number of under-insured cancer patients is increasing. This study outlines predictors of financial toxicity and emphasizes that having health insurance does not prevent patients from having financial distress or health disparities.PubMedCentralCrossRefPubMed
3.
Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(14):1608–14.CrossRef
4.
Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014;20(9):1375–81.CrossRef
5.
Jagsi R, Pottow JAE, Griffith KA, Bradley C, Hamilton AS, Graff J, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014;24:2014.
6.•
Kent EE, Forsythe LP, Yabroff KR, Weaver KE, de Moor JS, Rodriguez JL, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710–7. 32% of patients reported cancer-related financial problames making patinets more likely to forgo or delay their medical care. Factors found to be significantly associated with cancer-related financial problems were younger age at diagnosis, minority/race/ethnicity, history of chemotherapy or radiation treatment, recurrence or multiple cancer, and shorter time from diagnosis.PubMed
7.
Kodama Y, Morozumi R, Matsumura T, Kishi Y, Murashige N, Tanaka Y, et al. Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey. BMC Cancer. 2012;12:152.PubMedCentralCrossRefPubMed
8.
Langa KM, Fendrick AM, Chernew ME, Kabeto MU, Paisley KL, Hayman JA. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004;7(2):186–94.CrossRefPubMed
9.
Majhail NS, Rizzo JD, Hahn T, Lee SJ, McCarthy PL, Ammi M, et al. Pilot study of patient and caregiver out-of-pocket costs of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(6):865–71.PubMedCentralCrossRefPubMed
10.
Selden TM, Kenney GM, Pantell MS, Ruhter J. Cost sharing in medicaid and CHIP: how does it affect out-of-pocket spending? Health Aff. 2009;28(4):w607–19.CrossRef
11.
Meneses K, Azuero A, Hassey L, McNees P, Pisu M. Does economic burden influence quality of life in breast cancer survivors? Gynecol Oncol. 2012;124(3):437–43.PubMedCentralCrossRefPubMed
12.
Goodwin JA, Coleman EA, Sullivan E, Easley R, McNatt PK, Chowdhury N, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs. 2013;36(4):301–8.PubMedCentralCrossRefPubMed
13.•
Hamilton JG, Wu LM, Austin JE, Valdimarsdottir H, Basmajian K, Vu A, et al. Economic survivorship stress is associated with poor health-related quality of life among distressed survivors of hematopoietic stem cell transplantation. Psycho-Oncology. 2013;22(4):911–21. This study showed that financial stress was associated with poor health related quality of life. More specifically, greater perceptions of financial and employment stress were associated with poorer physical, functional and transplant-specific functioning. Greater financial stress was also associated with poorer emotional functioning.PubMedCentralCrossRefPubMed
14.
Chino F, Peppercorn J, Taylor DH, Lu Y, Samsa G, Abernethy A, et al. Self-reportef financial burden and satisfaction wit care among patients with cancer. Oncologist. 2014;19:414–20.PubMedCentralCrossRefPubMed
15.
Khera N. Reporting and grading financial toxicity. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(29):3337–8.CrossRef
16.
Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, et al. Impact of financial burden of cancer on survivors’ quality of life? J Oncol Pract. 2014;27:2014.
17.•
Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(4):306–11. This study showed that patients with higher copayments are more likely to discontiue or be nonadherent to Tyrosine Kinase Inhibitors.CrossRef
18.
19.
Guy GP, Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013;31(30):3749–57.PubMedCentralCrossRefPubMed
20.•
Azzani M, Roslani AC, Su TT. The perceived cancer-related financial hardship among patients and their families: a systematic review. Support Care Cancer. 2015;23(3):889–98. This systematic review includes international studies and does an excellent job of summarizing the issues for patients and families, how financial hardship is manifested, and what can be done to predict and ameliorate financial toxicity.CrossRefPubMed
21.
Head BA, Faul AC. Development and validation of a scale to measure socioeconomic well-being in persons with cancer. J Support Oncol. 2008;6(4):183–92.PubMed
22.
de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120(20):3245–53.CrossRefPubMed
23.
Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood). 2001;20(6):267–78.CrossRef
24.
Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119(6):1257–65.CrossRefPubMed
25.
Palmer NR, Geiger AM, Lu L, Case LD, Weaver KE. Impact of rural residence on forgoing healthcare after cancer because of cost. Cancer Epidemiol Biomarkers Prev. 2013;22(10):1668–76.CrossRefPubMed
26.
27.
Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff. 2013;32(6):1143–52.CrossRef
28.
Sharp L, Carsin A-E, Timmons A. Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer. Psycho-Oncology. 2013;22(4):745–55.CrossRefPubMed
29.
Weaver KE, Rowland JH, Bellizzi KM, Aziz NM. Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States. Cancer. 2010;116(14):3493–504.PubMedCentralCrossRefPubMed
30.
Berkowitz SA, Meigs JB, DeWalt D, Seligman HK, Barnard LS, Bright OJ, et al. Material need insecurities, control of diabetes mellitus, and use of health care resources: results of the measuring economic insecurity in diabetes study. JAMA Intern Med. 2015;175(2):257–65.CrossRefPubMed
31.
Abel GA, Albelda R, Salas Coronado DY, Marcellot L, Hahn T, Khera N, et al. Prospective assessment of familial financial hardship after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(2, Supplement):S72.CrossRef
32.
Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58(1):9–31.CrossRefPubMed
33.
Pidala J, Craig BM, Lee SJ, Majhail N, Quinn G, Anasetti C. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(1):63–7.PubMedCentralCrossRefPubMed
34.
Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(2):233–7.CrossRef
35.•
Bullock AJ, Hofstatter EW, Yushak ML, Buss MK. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract. 2012. This study explores in depth the patients’ perspective on communicating with their physicians about the cost of cancer care, and showed that patients have a higher comfort level in discussing financial issues than their oncologists, with important implications for medical education.
36.
Alexander GC, Casalino LP, Tseng CW, McFadden D, Meltzer DO. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med. 2004;19(8):856–60.PubMedCentralCrossRefPubMed
37.
Kim W, McNulty J, Chang Y, Weise M, Hashmi S, Ailawadhi S, et al. Financial burden after allogeneic hematopoietic cell transplantation: a qualitative analysis from patient perspective. Bone Marrow Transplant. 2015.
38.
Alexander GC, Hall MA, Lantos JD. Rethinking professional ethics in the cost-sharing era. Am J Bioeth. 2006;6(4):W17–22.CrossRefPubMed
39.
40.
Ubel PA, Abernethy AP, Zafar SY. Full disclosure — out-of-pocket costs as side effects. N Engl J Med. 2013;369(16):1484–6.CrossRefPubMed
41.
Barcellos SH, Wuppermann AC, Carman KG, Bauhoff S, McFadden DL, Kapteyn A, et al. Preparedness of Americans for the affordable care act. Proc Natl Acad Sci U S A. 2014;111(15):5497–502.PubMedCentralCrossRefPubMed
42.
Collins SR RP, Doty M, Beutel S. The rise in health care coverage and affordability since health reform took effect findings from the Commonwealth Fund Biennial Health Insurance Survey, 2015.
43.
Wharam JF, Ross-Degnan D, Rosenthal MB. The ACA and high-deductible insurance — strategies for sharpening a blunt instrument. N Engl J Med. 2013;369(16):1481–4.CrossRefPubMed
44.
Saloner B, Sabik L, Sommers BD. Pinching the poor? Medicaid cost sharing under the ACA. N Engl J Med. 2014;370(13):1177–80.CrossRefPubMed
45.
Malin JL. Wrestling with the high price of cancer care: should we control costs by individuals’ ability to pay or society’s willingness to pay? J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(20):3212–4.CrossRef
Metadaten
Titel
Financial Hardship—an Unwanted Consequence of Cancer Treatment
verfasst von
Julie McNulty
Nandita Khera
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 3/2015
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-015-0266-1

Weitere Artikel der Ausgabe 3/2015

Current Hematologic Malignancy Reports 3/2015 Zur Ausgabe

Myelodysplastic Syndromes (D Steensma, Section Editor)

Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Myelodysplastic Syndromes (D Steensma, Section Editor)

Where Does Lenalidomide Fit in Non-del(5q) MDS?

Health Economics (N Khera, Section Editor)

Persistent Disparities in Adult Hematopoietic Cell Transplantation

Health Economics (N Khera, Section Editor)

Optimizing Quality and Efficiency of Healthcare Delivery in Hematopoietic Cell Transplantation

Myelodysplastic Syndromes (D Steensma, Section Editor)

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)

The GHSG Approach to Treating Hodgkin’s Lymphoma

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise